Safety and preliminary efficacy analysis of the mtor inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer

Clinical Genitourinary Cancer

Volumn 10, Issue 4, 2012, Pages 232-238

  Amato, Robert J ^a   Wilding, George ^b   Bubley, Glenn ^c   Loewy, John ^d   Haluska, Frank ^d   Gross, Mitchell E ^e  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d ARIAD PHARMACEUTICALS INC   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Combination therapy; Disease stabilization; Phase II; Prostate specific antigen; Targeted therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; RIDAFOROLIMUS; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EPISTAXIS; ERYTHEMA; FATIGUE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; INJECTION SITE INFLAMMATION; MALE; MOUTH ULCER; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; STOMATITIS; THROMBOCYTOPENIA; TONGUE ULCER; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SIROLIMUS; TAXOIDS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84868591659     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.05.001     Document Type: Article

References (29)

1. American Cancer Society Cancer Facts and Figures 2010 2010 American Cancer Society Atlanta
2. Surveillance Epidemiology and End Results Program SEER Stat Fact Sheets: Prostate http://seer.cancer.gov/statfacts/html/prost.html Accessed: May 29, 2012
3. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology: prostate cancer http://www.nccn.org/professionals/physician-gls/f- guidelines.asp#prostate Accessed: May 29, 2012
4. D.P. Petrylak, C.M. Tangen, M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
5. I.F. Tannock, R. de Wit, W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
6. D.R. Berthold, G.R. Pond, F. Soban Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2008 242 245
7. J.A. Garcia, D. Danielpour Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies Mol Cancer Ther 7 2008 1347 1354
8. J.S. Rai, M.J. Henley, H.L. Ratan Mammalian target of rapamycin: a new target in prostate cancer Urol Oncol 28 2010 134 138
9. B.S. Taylor, N. Schultz, H. Hieronymus Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
10. A.S. Fung, L. Wu, I.F. Tannock Concurrent and sequential administration of chemotherapy and the mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts Clin Cancer Res 15 2009 5389 5395
11. P.M. Ghosh, S.N. Malik, R.G. Bedolla Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation Endocr Relat Cancer 12 2005 119 134
12. C.W. Kinkade, M. Castillo-Martin, A. Puzio-Kuter Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model J Clin Invest 118 2008 3051 3064
13. T. Kobayashi, Y. Shimizu, N. Terada Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by rheb in prostate cancer cell proliferation Prostate 70 2010 866 874
14. T.M. Morgan, T.E. Pitts, T.S. Gross RAD001 (everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid Prostate 68 2008 861 871
15. Y. Wang, M. Mikhailova, S. Bose Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival Oncogene 27 2008 7106 7117
16. L. Wu, D.C. Birle, I.F. Tannock Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts Cancer Res 65 2005 2825 2831
17. W. Zhang, J. Zhu, C.L. Efferson Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a PTEN-deficient mouse model of prostate cancer Cancer Res 69 2009 7466 7472
18. P.K. Majumder, P.G. Febbo, R. Bikoff MTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways Nat Med 10 2004 594 601
19. M. Mita, K. Sankhala, I. Abdel-Karim Deforolimus (AP23573) a novel mTOR inhibitor in clinical development Expert Opin Investig Drugs 17 2008 1947 1954
20. M.M. Mita, A.C. Mita, Q.S. Chu Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies J Clin Oncol 26 2008 361 367
21. C.M. Hartford, A.A. Desai, L. Janisch A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies Clin Cancer Res 15 2009 1428 1434
22. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
23. H.I. Scher, S. Halabi, I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
24. H.I. Scher, M.J. Morris, W.K. Kelly Prostate cancer clinical trial end points: "RECIST"ing a step backwards Clin Cancer Res 11 2005 5223 5232
25. K. Chamie, P.M. Ghosh, T.M. Koppie The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer Am J Transplant 8 2008 2668 2673
26. B. Cinar, A. De Benedetti, M.R. Freeman Post-transcriptional regulation of the androgen receptor by mammalian target of rapamycin Cancer Res 65 2005 2547 2553
27. S. Sharef, J. Jac, M. Khan Rapamycin for androgen independent prostate cancer (AIPC) 2006 ASCO Annual Meeting Proceedings Part I J Clin Oncol 24 18S) 2006 Abstract 14584
28. P. Ohorodnyk, E.A. Eisenhauer, C.M. Booth Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point? Eur J Cancer 45 2009 2249 2252
29. U. Emmenegger, S.S. Sridhar, C.M. Booth A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC) J Clin Oncol 28 15s 2010 TPS246